B-cell Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for B-cell Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-03-17Clinical Trial Update: JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Lymphoma [NA]
Clinical trial update for JY231 injection for relapsed or refractory B-cell non-Hodgkin lymphoma; the study status is not yet recruiting.
-
CLINICAL_TRIALS research · 2025-03-04Clinical Trial Update: Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL [Phase 1]
Phase 1 clinical trial evaluating cord blood-derived CAR-NK cells targeting CD19 for refractory or relapsed B-cell non-Hodgkin lymphoma.
-
CLINICAL_TRIALS trial_result · 2025-02-28Clinical Trial Update: Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial update reporting results from a Phase 1/2 study of a conditioning regimen using gemcitabine hydrochloride, clofarabine, and b…
-
CLINICAL_TRIALS trial_result · 2025-02-18Clinical Trial Update: C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 study of C752 in patients with refractory/relapsed B-cell non-Hodgkin lymphoma has been terminated.
-
CLINICAL_TRIALS research · 2025-02-12Clinical Trial Update: A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 clinical trial update for CT1190B in relapsed/refractory B-cell non-Hodgkin lymphoma, currently recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-02-07Clinical Trial Update: Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL [Phase 1]
This is a Phase 1 clinical trial evaluating the combination of pembrolizumab with TGR-1202 (umbralisib) in relapsed/refractory chronic lymph…
-
CLINICAL_TRIALS research · 2025-01-24Clinical Trial Update: Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL [Phase 2]
A Phase 2 clinical trial is evaluating immunobridging/maintenance therapy versus non-bridging therapy in CAR-T treatment for low-risk relaps…
-
CLINICAL_TRIALS research · 2025-01-07Clinical Trial Update: A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating subcutaneous epcoritamab as monotherapy or with standard-of-care therapies in adults in China with B-c…
-
CLINICAL_TRIALS research · 2025-01-03Clinical Trial Update: A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 clinical trial evaluating CT1190B for relapsed/refractory B-cell non-Hodgkin lymphoma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-12-18Clinical Trial Update: A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Phase Ib/II trial evaluating mosunetuzumab in combination with CHOP or CHP-Polatuzumab Vedotin in B-cell non-Hodgkin lymphoma; the study has…
-
CLINICAL_TRIALS trial_result · 2024-12-11Clinical Trial Update: TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas [Phase 1]
Phase 1 trial evaluating SD-101 (TLR9 agonist) and BMS-986178 (anti-OX40 antibody) with radiation therapy for low-grade B-cell non-Hodgkin l…
-
CLINICAL_TRIALS trial_result · 2024-12-10Clinical Trial Update: High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement [Phase 2]
Phase 2 study evaluating high-dose sequential chemoimmunotherapy for B-cell lymphomas with central nervous system involvement has completed …
-
CLINICAL_TRIALS research · 2024-12-10Clinical Trial Update: A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma [Phase 1]
This update reports on a Phase 1 clinical trial of JMT601 in relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma, currently rec…
-
CLINICAL_TRIALS research · 2024-12-04Clinical Trial Update: Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research [EARLY_Phase 1]
This clinical trial from Zhejiang University is evaluating the safety and potential efficacy of Meta10-19 metabolically armed CD19 CAR-T cel…
-
CLINICAL_TRIALS trial_result · 2024-12-03Clinical Trial Update: Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies [Phase 2]
This Phase 2 trial studied the combination of lenalidomide and ipilimumab after stem cell transplantation in patients with hematologic or ly…
-
CLINICAL_TRIALS trial_result · 2024-11-21Clinical Trial Update: MB-CART20.1 Lymphoma [Phase 1, Phase 2]
Miltenyi Biomedicine's MB-CART20.1 Lymphoma trial in relapsed or refractory B-cell non-Hodgkin lymphoma and non-Hodgkin lymphoma has complet…
-
CLINICAL_TRIALS research · 2024-11-21Clinical Trial Update: To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL) [Phase 2]
A Phase 2 trial is evaluating the safety and efficacy of autologous CD19 CAR-T cells for relapsed/refractory B-cell non-Hodgkin lymphoma.
-
CLINICAL_TRIALS trial_result · 2024-11-19Clinical Trial Update: An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma [EARLY_Phase 1]
An early Phase 1 clinical study is evaluating the safety and preliminary efficacy of AcNK-Sup003 cell injections for relapsed or refractory …
-
CLINICAL_TRIALS research · 2024-11-07Clinical Trial Update: JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia [NA]
Clinical trial update for JY231 Injection studying its use in relapsed or refractory B-cell lymphoma and B-cell acute lymphoblastic leukemia…
-
CLINICAL_TRIALS research · 2024-11-06Clinical Trial Update: Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 trial evaluating a CD19/CD20 dual-targeted cell therapy for relapsed or refractory B-cell non-Hodgkin lymphoma is currently recrui…
-
CLINICAL_TRIALS research · 2024-11-01Clinical Trial Update: ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT [Phase 2]
Phase 2 trial update on ARTA-based chemo-free bridging and maintenance therapy accompanying CAR-T treatment for high-risk relapsed/refractor…
-
CLINICAL_TRIALS research · 2024-10-21Clinical Trial Update: Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial evaluating BAFF CAR-T cells (LMY-920) for non-Hodgkin lymphoma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies [Phase 1]
Phase 1 study of CAR20.19.22 T-cells in relapsed/refractory B-cell malignancies has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-08-23Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma [Phase 1]
A Phase 1 study evaluating RO7443904 in combination with glofitamab for relapsed/refractory B-cell non-Hodgkin lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-07-25Clinical Trial Update: Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma [Phase 1]
Phase I dose-escalation study of oral S-55746 in patients with chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma completed.